--- title: "NP47724 NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A & B (CM/PHS/22/5661)" ocid: "ocds-r6ebe6-0000772000" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000772000" markdown_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000772000.md" json_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000772000.json" source: "Public Contracts Scotland" current_stage: "Award" buyer: "THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS)" published: "2024-07-10" --- # NP47724 NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A & B (CM/PHS/22/5661) Buyer: THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS) Current stage: Award OCID: ocds-r6ebe6-0000772000 [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000772000) [Download OCDS JSON](https://d3tenders.com/contract/ocds-r6ebe6-0000772000.json) ## Summary The Common Services Agency (NHS National Services Scotland) (NSS) has completed the procurement process for the "NP47724 NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A & B" in Edinburgh, UK. The industry category is Health, and relevant key dates include the award date on 10th July 2024. The procurement stage was an open procedure. This tender provides opportunities for large-scale suppliers in the health industry to supply products for treating Blood Disorders, including Haemophilia A & B to NHS Scotland. Businesses involved in the supply of pharmaceutical products and services, such as Takeda UK Limited, Pfizer Limited, and Octapharma Ltd, would be well-suited to compete for this tender and potentially grow their businesses through this framework agreement. ## Notice Supply of products for the treatment of Blood Disorders including Haemophilia A & B to NHS Scotland. ### Lot Information Standard Half-life Recombinant Factor VIII NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Enhanced Half-life Recombinant Factor VIII NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Enhanced Half-life Recombinant Factor VIII NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Eftrenonacog alfa (rFIX EHL) NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Eftrenonacog alfa (rFIX EHL) NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Nonacog beta pegol (rFIX EHL) NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. rFIX - Standard Half Life NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Recombinant Factor VII NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Porcine Factor VIII - susoctocog alfa NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Factor VIII Inhibitor Bypassing Fraction NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Factor IX - High Purity Factor IX NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Factor X NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Factor XIII - Plasma Derived NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Factor XIII - Recombinant NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Von willebrands factor / Factor VIII NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Von willebrands factor - Plasma Derived NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Von willebrands factor - Recombinant NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Fibrinogen Concentrate NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Prothrombin Complex dried NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Protein C Concentrate NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Fresh Frozen Plasma (all blood groups) NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. ## Key Details | Field | Value | | --- | --- | | Publication source | Public Contracts Scotland | | Latest notice | https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=JUL509597 | | Notice type | PCS Notice - Website Contract Award Notice | | Procurement type | Framework | | Procurement category | Goods | | Procurement method | Open | | Procurement method details | Open procedure | | Tender suitability | Not specified | | Awardee scale | Large | | All stages | Award | ## Dates | Field | Value | | --- | --- | | Publication date | 10 Jul 2024 | | Submission deadline | Not specified | | Future notice date | Not specified | | Award date | 31 May 2024 | | Contract period | Not specified | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | Not specified | | Lots value | Not specified | | Awards value | Not specified | | Contracts value | £85,293,871 | ## Status | Field | Value | | --- | --- | | Tender status | Complete | | Lots status | Complete | | Awards status | Not specified | | Contracts status | Active | ## Buyer | Field | Value | | --- | --- | | Main buyer | THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS) | | Locality | EDINBURGH | | Post town | Edinburgh | | Postcode | EH12 9EB | | Country | Scotland | | ITL 1 | TLM Scotland | | ITL 2 | TLM1 East Central Scotland | | ITL 3 | TLM13 City of Edinburgh | | Local authority | City of Edinburgh | | Electoral ward | Drum Brae/Gyle | | Westminster constituency | Edinburgh South West | | Delivery location | TLM Scotland | ## Supplier | Field | Value | | --- | --- | | Number of suppliers | 9 | | Supplier names | BIO PRODUCTS LABORATORY; CSL BEHRING; LFB BIOPHARMACEUTICALS; NOVO NORDISK; OCTAPHARMA; PFIZER; ROCHE PRODUCTS; SWEDISH ORPHAN BIOVITRUM; TAKEDA | ## CPV Codes ### Divisions - 33 - Medical equipments, pharmaceuticals and personal care products ### Codes - 33141530 - Blood coagulants - 33600000 - Pharmaceutical products ## Release History - 10 Jul 2024 at 00:00 - Award - PCS Notice - Website Contract Award Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=JUL509597 ## Documents - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=JUL509597 NP47724 NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A & B (CM/PHS/22/5661) - Supply of products for the treatment of Blood Disorders including Haemophilia A & B to NHS Scotland. ## Notice URLs - http:// - http://www.nss.nhs.scot/browse/procurement-and-logistics - https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000772000 ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000772000. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-r6ebe6-0000772000.json.